Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan - Archive ouverte HAL Access content directly
Journal Articles Clinical Colorectal Cancer Year : 2019

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan

(1) , (2) , (3) , (4) , (1) , (5) , (2) , (6) , (7) , , (1) , (6) , (8) , , (9) , (1) , (1) , , (2) , , (7) , (2) , (10) , (1) ,
1
2
3
4
5
6
7
8
9
10
Elisa Sperti
  • Function : Author
Julien Edeline
Rosella Spadi
  • Function : Author
Cindy Neuzillet
Mario Clerico
  • Function : Author
Paola Buscaglia
  • Function : Author
Francesco Montagnani
  • Function : Author

Abstract

BACKGROUND:FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) is an option for fit patients with metastatic (MPC) and locally advanced unresectable (LAPC) pancreatic cancer. However, no criteria reliably identify patients with better outcomes.PATIENTS AND METHODS:We investigated putative prognostic factors among 137 MPC/LAPC patients treated with triplet chemotherapy. Association with 6-month survival status (primary endpoint) was assessed by multivariate logistic regression models. A nomogram predicting the risk of death at 6 months was built by assigning a numeric score to each identified variable, weighted on its level of association with survival. External validation was performed in an independent data set of 206 patients. The study was registered at ClinicalTrials.gov (NCT03590275).RESULTS:Four variables (performance status, liver metastases, baseline carbohydrate antigen 19-9 level, and neutrophil-to-lymphocyte ratio) were found to be associated with 6-month survival by multivariate analysis or had sufficient clinical plausibility to be included in the nomogram. Accuracy was confirmed in the validation cohort (C index = 0.762; 95% confidence interval, 0.713-0.825). After grouping all cases, 4 subsets with different outcomes were identified by 0, 1, 2, or > 2 poor prognostic features (P < .0001).CONCLUSION:The nomogram we constructed accurately predicts the risk of death in the first 6 months after initiation of FOLFIRINOX in MPC/LAPC patients. This tool could be useful to guide communication about prognosis, and to inform the design and interpretation of clinical trials.
Fichier principal
Vignette du fichier
Fornaro et al-2019-Validated nomogram predicting 6-month survival in pancreatic cancer patients.pdf (1.49 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-02307162 , version 1 (18-05-2020)

Identifiers

Cite

Lorenzo Fornaro, Francesco Leone, Angélique Vienot, Andrea Casadei-Gardini, Caterina Vivaldi, et al.. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Clinical Colorectal Cancer, 2019, 18 (4), pp.e394-e401. ⟨10.1016/j.clcc.2019.08.004⟩. ⟨hal-02307162⟩
56 View
235 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More